Your session is about to expire
← Back to Search
TAR-200 + Cetrelimab vs BCG for Bladder Cancer (SunRISe-3 Trial)
SunRISe-3 Trial Summary
This trial looks at survival rates of bladder cancer patients who have never had BCG treatment, comparing two treatments to BCG.
SunRISe-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSunRISe-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SunRISe-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- All visible signs of my bladder cancer have been surgically removed.I have a history of urinating more than usual, with over 4 liters in a day.My bladder cancer is advanced and cannot be surgically removed.I do not have a permanent catheter, but I may use one temporarily.All side effects from my previous treatments have mostly gone away.I have never had BCG therapy or stopped it over 3 years ago.My bladder cancer is aggressive but hasn't spread into the muscle, and I haven't had BCG treatment.I do not have any bladder or urethral conditions that would make it unsafe to insert or remove medical devices.My bladder cancer has not spread outside the bladder, except for certain treated cases.I can take care of myself and am up and about more than half of my waking hours.
- Group 1: Treatment Group A: TAR-200 + Cetrelimab
- Group 2: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture
- Group 3: Treatment Group C: TAR-200 Alone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many facilities are currently hosting this research endeavor?
"This trial is presently seeking out patients from 40 diverse locations, including Little Rock, Duarte and Los Angeles. To lessen travel-related strain for participants, it is advised to enroll in the closest site available."
Has the Food and Drug Administration (FDA) granted authorization for Treatment Group A: TAR-200 + Cetrelimab?
"The combination of TAR-200 and Cetrelimab has been found to be relatively safe, with available data supporting their efficacy in a clinical setting. Therefore, our team at Power assigned this treatment program an overall score of 3."
Are there any vacancies to join this clinical trial?
"As indicated on clinicaltrials.gov, this research endeavour is no longer actively recruiting participants, having been posted in March of 2023 and last updated in late January of the same year. Despite not being an available opportunity for now, there are still 364 medical trials that require patient volunteers at present."
Share this study with friends
Copy Link
Messenger